Jessica K. Gordon, MD
Rheumatology
Jessica K. Gordon, MD
Belaire Building
7th Floor
525 East 71st Street
New York, NY 10021
Tel: 212.606.1173
fax: 212.774.2358
Belaire Building
7th Floor
525 East 71st Street
New York, NY 10021
Tel: 212.606.1173
fax: 212.774.2358
Dr. Jessica Gordon is an Associate Attending Physician in the Division of Rheumatology at Hospital for Special Surgery and an Associate Professor of Clinical Medicine at Weill Cornell Medicine. She specializes in the treatment of patients with systemic sclerosis (scleroderma), and her research focus is developing improved therapies for patients with this condition. She also specializes in the care patients with Raynaud phenomenon, mixed connective tissue disease, interstitial lung disease associated with connective tissue disease, Sjogren’s syndrome, systemic lupus erythematosus, rheumatoid arthritis, and other conditions. She is the HSS Scleroderma clinic chief. She has been recognized for several years as a "Top Doctor" by Castle/Connolly and New York magazine.
Dr. Gordon completed her undergraduate studies at Brown University in 1993. She received her MD degree from State University of New York at Stony Brook where she graduated Alpha Omega Alpha. She completed her internal medicine residency and chief residency at Georgetown University Hospital in Washington, DC. She then went on to complete her fellowship in Rheumatology at Hospital for Special Surgery. Following this she joined the faculty at HSS in 2010 where she continues to practice Rheumatology.
Dr. Gordon conducts clinical and translational research in systemic sclerosis. She is an investigator in multiple clinical trials and observational studies with this focus. She has been the recipient of numerous grants and awards including the Kellen Family Clinical Scientist Development Award, the Scleroderma Foundation New Investigator Grant, the Charles L. Christian Award for Excellence in Musculoskeletal Research, and the American College of Rheumatology Distinguished Fellow Award.
Patient Stories
Appointments
Associate Attending Physician, Hospital for Special Surgery
Associate Professor of Medicine, Weill Cornell Medical College
Departments
Specialized Centers
Special Expertise
Associated interstitial lung disease
Connective tissue disease
Eosinophilic fasciitis
Inflammatory arthritis
Inflammatory myopathy
Localized scleroderma/Morphea
Mixed connective tissue disease
Raynaud phenomenon
Rheumatoid arthritis
Sjogren’s syndrome
Systemic lupus erythematosus
Systemic sclerosis/scleroderma
Procedures
Intra-articular and intra-bursal aspirations and injections
Awards
Castle Connolly Top Doctors in New York Metro Area, 2017-2021
Castle Connolly Regional Top Doctor, 2017-2021
New York Magazine Top Doctors, 2017-2021
Exceptional Women In Medicine: 2019, 2020
Charles L. Christian Award for Excellence in Musculoskeletal Research, 2010
Department of Medicine Fellow Award - Finalist, 2010
American College of Rheumatology Distinguished Fellow Award, 2009
Certificate of Appreciation – Scleroderma Foundation – Tristate Chapter, 2009
Donald Knowlan Award, Georgetown University Hospital, Dept. of Internal Medicine, 2005
Janet Glasgow Memorial Achievement Citation, American Medical Women’s Society, 2002
Alpha Omega Alpha Honor Society, 2001
Affiliations
Member, American College of Rheumatology
Member, American Medical Association
Scleroderma Foundation Medical Advisory Board
Languages
English, Spoken by Office Staff: Spanish
Insurance Information
Please do not hesitate to contact our office if you have questions regarding your insurance coverage. You may have coverage subject to the availability of 'out-of-network' benefits.
Patient ratings for Dr. Gordon
Industry Relationships
One of the goals of HSS is to advance the science of orthopedic surgery, rheumatology, and related disciplines for the benefit of patients. Physicians at HSS may collaborate with outside companies for education, research and medical advances. HSS supports this collaboration in order to foster medical breakthroughs; however HSS also believes that these collaborations must be disclosed.
As part of the disclosure process, this website lists physician collaborations with outside companies. The disclosures are provided by information provided by the physician and other sources and are updated regularly. Further information may be available on individual company websites.
Below are the healthcare industry relationships reported by Dr. Gordon as of December 16, 2019.
- Corbus Pharmaceuticals- Consultant
- Cumberland Pharmaceuticals- Research Support
- EICOS Sciences - Advisory Board
- Genentech- Research Support
- Medpace, Inc. - Research Support
- Putnam Associates - Consultant
- Regents of UCLA - Research Support
- Scleroderma Research Foundation - Research Support
By disclosing the collaborations of HSS physicians with industry on this website, HSS and its physicians make this information available to their patients and the public, thus creating a transparent environment for those who are interested in this information. Further, the HSS Conflicts of Interest Policy does not permit physicians to collect royalties on products developed by him/her that are used on patients at HSS.
Patients should feel free to ask their HSS physicians questions about these relationships.
Dr. Gordon in the News
Education
MD, State University of New York at Stony Brook, Stony Brook, NY 2002
MS, Clinical Investigation, Cornell University, NY 2010
Internship
Residency
Fellowship
Certification
Rheumatology, 2008
Internal Medicine, 2005
State Licensure
Patient Education by Dr. Gordon on HSS.edu
- Scleroderma and Systemic Sclerosis (SSc): An Overview
- Kellen Award Program Fosters Emerging Physician-Scientists
Blog Posts by Dr. Gordon
Selected Books by Dr. Gordon
- Gordon JK, Goldenberg D, Erkan D, Lockshin M. (2009) Difficult Situations in the Antiphospholipid Syndrome. Handbook of Systemic Autoimmune Diseases, Volume 10. Antiphospholipid Syndrome in Systemic Autoimmune Diseases. (Eds. Ricard Cervera, Joan Carles Reverter and Munther Khamashta), 215 – 233.
Selected Publications
Gordon JK, Martyanov V, Franks JM, Bernstein EJ, Szymonifka J, Magro C, Wildman HF, Wood TA, Whitfield ML, Spiera RF. Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial. Arthritis Rheumatol. 2017 Oct 26. doi: 10.1002/art.40358. PMID: 29073351.
Showalter K, Spiera R, Magro C, Agius P, Martyanov V, Franks JM, Sharma R, Geiger H, Wood TA, Zhang Y, Hale CR, Finik J, Whitfield ML, Orange DE, Gordon JK. Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement. Ann Rheum Dis. 2021 Feb;80(2):228-237. doi: 10.1136/annrheumdis-2020-217840. Epub 2020 Oct 7. PubMed PMID: 33028580.
Gordon JK, Martyanov V, Magro CM, Wildman HF, Wood TA, Huang WT, Crow MK, Whitfield ML, Spiera RF. Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial. Arthritis Research & Therapy. 2015; 17(1):213
Gordon JK, Udeh U, Doobay K, Magro C, Wildman HF, Davids M, Mersten JN, Huang WT, Lyman S, Crow MK, Spiera RF. Imatinib Mesylate (Gleevec™) in the Treatment of Diffuse Cutaneous Systemic Sclerosis: Results of a 24 Month Open Label, Extension Phase, Single Center Trial, Clin Exp Rheumatol. 2014 Nov-Dec;32(6 Suppl 86):S-189-93. Epub 2014 Aug 15.
Spiera RF, Gordon JK, Mersten JN, Magro CM, Mehta M, Wildman HF, Kloiber S, Kirou KA, Lyman S, Crow MK. Imatinib Mesylate (Gleevec™) in the Treatment of Diffuse Cutaneous Systemic Sclerosis: Results of a One Year, Phase IIa, Single Arm, Open Label Clinical Trial. Ann Rheum Dis. 2011 Jun;70(6):1003-9. Epub 2011 Mar 11.
Chia JJ, Zhu T, Chyou S, Dasoveanu DC, Carballo C, Tian S, Magro CM, Rodeo S, Spiera RF, Ruddle NH, McGraw TE, Browning JL, Lafyatis R, Gordon JK, Lu TT. Dendritic cells maintain dermal adipose-derived stromal cells in skin fibrosis. J Clin Invest. 2016 Nov 1;126(11):4331-4345.
Lofgren S, Hinchcliff M, Carns M, Wood T, Aren K, Arroyo E, Cheung P, Kuo A, Valenzuela A, Haemel A, Wolters PJ, Gordon J, Spiera R, Assassi S, Boin F, Chung L, Fiorentino D, Utz PJ, Whitfield ML, Khatri P. Integrated, multicohort analysis of systemic sclerosis identifies robust transcriptional signature of disease severity. JCI Insight. 2016 Dec 22;1(21):e89073.
Ah Kioon MD, Tripodo C, Fernandez D, Kirou KA, Spiera RF, Crow MK, Gordon JK, Barrat FJ. Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8. Sci Transl Med. 2018 Jan 10;10(423):eaam8458. doi: 10.1126/scitranslmed.aam8458. PMID: 29321259.
Rice LM, Mantero JC, Stifano G, Ziemek J, Simms RW, Gordon J, Domsic R, Lafyatis R. A Proteome-Derived Longitudinal Pharmacodynamic Biomarker for Diffuse Systemic Sclerosis Skin. J Invest Dermatol. 2017 Jan;137(1):62-70.
Chung L, Domsic RT, Lingala B, Alkassab F, Bolster M, Csuka ME, Derk C, Fischer A, Frech T, Furst DE, Gomberg-Maitland M, Hinchcliff M, Hsu V, Hummers LK, Khanna D, Medsger TA Jr, Molitor JA, Preston IR, Schiopu E, Shapiro L, Silver R, Simms R, Varga J, Gordon JK, Steen VD. Survival and predictors of mortality in systemic sclerosis associated pulmonary arterial hypertension: Outcomes from the PHAROS registry. Arthritis Care Res (Hoboken). 2013 Aug 27. doi: 10.1002/acr.22121.
For more publications, please see the PubMed listing.
Selected Presentations
- Gordon JK, Spiera RF, Mersten JN, Wildman HF, Taime Z, Hackett, NR, Vukelic S, Kirou K, Crow MK. Does Treatment with Imatinib Modify Gene Expression in the Skin and Peripheral Blood Mononuclear Cells of Patient with Systemic Sclerosis? American College of Rheumatology Scientific Meeting (Atlanta, GA, 2010.)
- Gordon JK, Gomberg-Maitland M, Segal B, Domsic R, Shah A, Hummers L, Steen V, Horn E and the PHAROS Investigators. Difficulty Using World Health Organization Criteria to Categorize Pulmonary Hypertension in Patients with Systemic Sclerosis. American College of Rheumatology Scientific Meeting (Atlanta, GA, 2010.)
- Spiera RF, Gordon JK, Mersten J, Magro CM, Mehta M, Wildman HF, Kloiber SA, Kirou KA, Lyman, S, Crow MK. Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis: Interim Results of a Phase IIa, One Year, Open Label Clinical Trial. American College of Rheumatology Scientific Meeting (Atlanta, GA, 2010.)
- Gordon JK, Vukelic S, Magro CM, Mersten J, Wildman HF, Crow MK, Kirou KA and Spiera RF. Histologic and Molecular Basis of Improved Skin Scores in Scleroderma Patients Treated with Imatinib Mesylate (Gleevec.) Abstract 1727. American College of Rheumatology Scientific Meeting (Philadelphia, PA, 2009.)
- Gordon JK, Mersten J, Lyman S, Kloiber SA, Wildman HF, Crow MK, Kirou KA and Spiera RF. Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis: Interim Results of a Phase IIa, One Year, Open Label Clinical Trial. Presentation 606. American College of Rheumatology Scientific Meeting (Philadelphia, PA, 2009.)
- Taimeh Z, Gordon JK, MacDermott EJ, Barillas L, Mersten J, Duculan R, Spiera RF, Crow MK, Kirou KA. Elevated sVEGFR-1 Is a Candidate Biomarker for Pulmonary Dysfunction in Patients with Systemic Sclerosis. Abstract 466. American College of Rheumatology Scientific Meeting (Philadelphia, PA, 2009.)
- Spiera RF Gordon JK Mehta M Kirou KA Lyman S Kloiber SA Crow MK. (2008). Phase IIa Trial of Imatinib Mesylate (Gleevec) in the Treatment of Diffuse Systemic Sclerosis - An Interim Analysis. Arthritis and Rheumatism 58(10): S1222.
- Gordon JK, Magid S, Berman E. (2008). Elevations in Creatine Kinase Occur Frequently in Patients Treated with Imatinib Mesylate (Gleevec.) Abstract F15/469, American College of Rheumatology Scientific Meeting (San Francisco, CA, 2008.)
- Gordon JK, Taimeh Z, Markopoulou A, Mersten J, Crow MK, Kirou KA. (2008). High Levels of Activated ERK in Monocytes of Patients with Scleroderma. Abstract F2/456, American College of Rheumatology Scientific Meeting (San Francisco, CA, 2008.)
- Gordon JK, Steen V. (2005). African American Scleroderma Patients Have Altered Body Image. Arthritis and Rheumatism 52(9): S585.
Research Interests
Scleroderma
Clinical Trials
- Abatacept (CTLA4-lg) for the Treatment of Relapsing, Non Severe, Granulomatosis with Polyangiitis (Wegener’s) (ABROGATE)
- Gleevec in the Treatment of Systemic Sclerosis - EXTENSION STUDY
- Scleroderma Registry and Repository (Old IRB #26069)
- Randomized, Double-Blind, Placebo-Controlled Trial of IL1-Trap, Rilonacept in Systemic Sclerosis-A Phase I/II Biomarker Trial (Old IRB #14115)
- The Myositis Registry and Repository - 2016
- VCRC Genetic Repository One Time DNA Protocol - 2016
- The Natural History and Outcome of Scleroderma Patients at High Risk or with Early Pulmonary Hypertension: a Multicenter Study Performed by from the Scleroderma Clinical Trials Consortium (PHAROS)
- Prospective Registry of Early Systemic Sclerosis (PRESS)- Phenotypic, Serologic, and Biomarker/Genetic Characteristics of Early Diffuse Cutaneous Scleroderma
- A Double Blind, Randomized, Placebo-Controlled Trial Evaluating Efficacy and Safety of Oral Nintedanib Treatment for at Least 52 Weeks in Patients with “Systemic Sclerosis associated Interstitial Lung Disease” (SSc-ILD)
- Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination with Azathioprine for the Maintenance of Remission in Wegener’s Granulomatosis and Microscopic Polyangiitis
- An International, Open Label, Randomized Controlled Trial Comparing Rituximab with Azathioprine as Maintenance Therapy in Relapsing ANCA-Associated Vasculitis
- The LOTUSS Trial: An Open-Label, Randomized, Phase 2 Study of the Safety and Tolerability of Pirfenidone When Administered to Patients With Systemic Sclerosis−Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)
- A Phase III, Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Assess the Efficacy and Safety of Tocilizumab in Subjects with Giant Cell Arteritis
- Natural History and Outcome of Scleroderma Patients at High Risk or with Early Pulmonary Hypertension
- ASCI: A Randomized, Double-blind, Placebo-controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis Associated Pulmonary Arterial Hypertension (SSc-PAH)
- Nilotinib in the Treatment of Systemic Sclerosis
- Bellumimab for the Treatment of Diffuse Cutaneous Systemic Sclerosis
- Prospective, Observational Safety Study Of Patients With Granulomatosis With Polyangiitis (Wegener’s) Or Microscopic Polyangiitis Treated With Rituximab
- Phase II/III, Multicenter, Randomized, Double-blind Placebo-Controlled Study to Assess the Efficacy and Safety of Tocilizumab vs. Placebo in Patients with Systemic Sclerosis
- Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Parallel group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients with Ischemic Digital Ulcers Associated with Systemic Sclerosis
- Phase IIa Trial of Tocilizumab in the Treatment of Polymyalgia Rheumatica
- The Myositis Registry and Repository - 2011
- Abatacept in Large Vessel Vasculitis
- VCRC Genetic Repository One Time DNA Protocol - 2013
Patient Registries
- Dr. Gordon is a principal investigator for these patient registries.